Gastrointestinal (GI) motility dysfunction is a major contributing factor to many disorders of the GI tract.
Gastrointestinal (GI) motility dysfunction refers to the abnormal rate and coordination of food moving out of the stomach and through the rest of the digestive tract. Reduced GI motility can cause symptoms of bloating, nausea, pain and constipation and can adversely affect quality of life. Disorders of reduced motility include chronic idiopathic constipation, constipation predominant irritable bowel syndrome, functional dyspepsia, and delayed gastric emptying.
Our investigational 5-HT4 receptor agonist compound, velusetrag (also known as
TD-5108), is under development for the treatment of gastroparesis in collaboration with Alfa Wassermann S.p.A.
The goal of our program is to develop an effective and well-tolerated medicine with once-a-day oral dosing.